The establishment of high-quality and ultimately immunogenic neoantigens necessitates a comprehensive assessment of multiple vital factors encompassing, among others, frequency of DNA mutations within the somatic cells of tumor tissue, expression levels of genes and transcripts, affinity of peptides to MHC molecules, the stability of peptide-MHC binding, the potential for peptide translocation to the cell surface, and the compatibility of the peptide with T cell receptor recognition (38, 39). Here, HLA-C is linked to neoplasm.